The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...

The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...